Selumetinib granted orphan designation in Europe for neurofibromatosis type 1

Pressmeddelanden   •   Aug 03, 2018 08:19 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Imfinzi receives positive EU CHMP opinion for locally- advanced, unresectable non-small cell lung cancer

Pressmeddelanden   •   Jul 27, 2018 15:03 CEST

Recommended marketing authorisation for patients whose tumours express PD-L1 on ≥1% of tumour cells Imfinzi is the first immunotherapy recommended for approval for the treatment of locally-advanced, unresectable NSCLC

AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2018

Pressmeddelanden   •   Jul 26, 2018 08:06 CEST

Starka resultat från nya läkemedel och tillväxtmarknaderna stödjer återgång till tillväxt under 2018

Atacand to be divested to Cheplapharm in Europe

Pressmeddelanden   •   Jul 24, 2018 08:12 CEST

AstraZeneca has agreed to sell the commercial rights to Atacand(candesartan cilexetil)and AtacandPlus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to CheplapharmArzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension.

Katarina Ageborg ny VD för AstraZeneca i Sverige

Pressmeddelanden   •   Jul 16, 2018 13:22 CEST

AstraZeneca meddelar i dag att Katarina Ageborg utsetts till ny VD för AstraZeneca AB. Hon tar över efter Jan-Olof Jacke den 1 augusti 2018 och kommer även fortsättningsvis rapportera till koncernchef Pascal Soriot.

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Pressmeddelanden   •   Jul 02, 2018 08:03 CEST

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s Lynparza

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Pressmeddelanden   •   Jul 02, 2018 08:02 CEST

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC).

Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes

Pressmeddelanden   •   Jun 29, 2018 16:09 CEST

AstraZeneca today announced that the CHMP of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release) for the treatment of type-2 diabetes.

Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer

Pressmeddelanden   •   Jun 27, 2018 08:02 CEST

AstraZeneca and MSD today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.

AstraZeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA 2018

Pressmeddelanden   •   Jun 19, 2018 08:02 CEST

Key data evaluating the efficacy and safety of Farxiga (dapagliflozin) in combination with other type-2 diabetes therapies head-to-head vs. insulin or sulfonylurea Latest data from the DEPICT clinical programme evaluating Farxiga to address an unmet need for oral therapy in adult patients with type-1 diabetes

Kontaktpersoner 3 kontaktpersoner

  • Presskontakt
  • Extern kommunikationsdirektör
  • dydtucosjaalcob.luaatynd@astrazedbneqybecaui.crlom
  • 08 553 260 20 Mobil: 072 560 21 57

Om AstraZeneca

Om AstraZeneca

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. Bolaget är också selektivt aktivt inom autoimmunitet, neurovetenskap och infektion. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se